Navigation Links
Homozygous in Medical News

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

... from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients and ... from our Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia patients. We ... is planning an initial European submission for homozygous Familial Hypercholesterolemia (FH) with timing ...

Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008

... from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients and ... 3 study evaluating mipomersen in patients with homozygous FH. Also we and our partners expect to report ... enrollment in a Phase 3 mipomersen study in homozygous FH subjects. Initiating four additional ...

What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?

... There are three predominant genotypes of TS: (1) homozygous with two tandem repeats (2R/2R); (2) homozygous with three tandem repeats (3R/3R); (3) ... (n = 22) and 3R/3R (n = 40). Patients who were homozygous for triple-repeated (3R/3R) sequences showed ...

The onchocerciasis parasite showing signs of resistance

... the percentage of parasites showing a genotype homozygous for this gene fell from 79 to 31% in subjects ... inferred that the parasites showing a genotype homozygous for β-tubulin are more susceptible to it. As ... there were more microfilariae in the uterus of homozygous female parasites than in those of heterozygous ...

GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.

... pain in a patient on therapy with lovastatin. homozygous Familial Hypercholesterolemia MEVACOR is less effective in patients with the rare homozygous familial hypercholesterolemia, possibly because ... (see ADVERSE REACTIONS) in these homozygous patients. Information for Patients Patients ...

IDO2 an active enzyme to target in pancreatic cancer

... to have an active IDO2 enzyme. Nineteen percent of the patients were homozygous wild-type, meaning they had two active alleles, and 42 percent of the ... meaning they had one active allele. Twenty-five percent were homozygous for two inactive IDO2 alleles. The remaining 14 percent were difficult to ...

Scientists identify new congenital neutropenia syndrome and causative gene mutation

... the other is not) in the neutrophil elastase (ELA2) gene. In 2007, Klein's lab identified another causative mutation in a subgroup of SCN patients: homozygous mutations (where the defect is present in both copies of the gene) in the HAX1 gene. To conduct the current study, the researchers focused on five ...

ADHD Gene Doesn't Predict Response to Drugs

... "What we found is that the children who have two copies of the Val isoform had an even harder time orienting their goals than children who are homozygous for Met [that is, have two copies of the Met isoform] or even Val/Met," he said. Each person two copies of the COMT gene, one from each parent. ...

Isis Reports Financial Results and Highlights for First Quarter of 2008

... Phase 3 program in patients with high cholesterol at high risk for cardiovascular disease including an ongoing Phase 3 study in patients with homozygous Familial Hypercholesterolemia (FH). o Isis reported updated safety data on mipomersen from an ongoing open-label extension study in ...

FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen

... has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH). The FDA will require data from two ongoing preclinical studies for carcinogenicity to be included in the hoFH ...

Isis Reports Financial Results and Highlights for Fiscal year 2007

... strong progress with our most important asset, mipomersen. Earlier in the year, we announced the initiation of the Phase 3 studies in patients with homozygous Familial Hypercholesterolemia. Today we are announcing that we are initiating the rest of the Phase 3 program for mipomersen including studies in ...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

... cholesterol levels with statins alone or who are intolerant of statins. Mipomersen is currently in phase 3 development for patients with homozygous familial hypercholesterolemia, and a U.S. marketing application for this indication is anticipated in 2009. The product offers an innovative ...

Human embryonic stem cell lines created that avoid immune rejection

... and the subsequent derivation of cell lines having the morphology and markers characteristic of human embryonic stem cells. In a paper entitled, HLA homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts, the authors emphasize two key factors that would make this technology so valuable for ...

Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations

... have substantiated and replicated the links of CFH, CFB and Chromosome 10 to AMD. Additional research published in 2007 found that people with homozygous risk profiles for CFH, CFB and LOC387715/HTRA1 have as great as a 250 times increased risk of developing AMD. About Optherion: Optherion, Inc. is ...

Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months

... the most severely affected patients may need apheresis, an expensive and time-consuming procedure that removes the "bad" cholesterol from the blood. homozygous FH is rare, affecting about one in one million people, but heterozygous FH is much more common with a prevalence of approximately one in every 500 ...

Study Questions Genetic Screening for Treatable Diseases

... Research Institute in La Jolla, Calif., said, "Not until clinicians and researchers better understand the factors that determine whether a patient homozygous for the N370S (GD) mutation will develop severe disease or none at all will screening for Gaucher disease become useful. Until then, screening for ...

New Therapy to Treat Patients With Severely Elevated Cholesterol Levels

... of Medicine (NEJM). In this study, patients with homozygous familial hypercholesterolemia (FH), a high-risk ... designed and carried out the current study in homozygous FH patients with support from the Doris Duke ... as AEGR-733. Patients who suffer from homozygous FH typically respond poorly to standard drug ...

Gene Responsible for Blindness in Infants and Children Identified

... the UK, Dr. Koenekoop and his team, including Dr. Irma Lopez, used a new technique called SNP (single nucleotide polymorphism) technology to identify homozygous regions in the genome, which led to the discovery of the new gene called LCA5. In the past, large families were necessary to find genes, but ...

Genetic Variation Linked to Age-Related Macular Degeneration

... up in the retina of the eye) to vision-disabling late AMD and the risks increased with each successive stage to stage 11 for late AMD. Individuals homozygous (having two identical gene alleles at the corresponding site on a chromosome) for the CFH Y402H gene had a 48 percent cumulative risk of developing ...

Cigarette Smoking and High Body Mass Index Increase the Risk of AMD

... cigarette smoking was associated with a fivefold increased risk and high BMI (30 or higher) was associated with a twofold higher risk of AMD. The homozygous risk genotype (CC) plus smoking conferred a tenfold higher risk of AMD, compared with non-smokers with the non-risk (TT) genotype, while the risk ...

CCR5 Mutation Confers Immunity Against HIV But Not Against West Nile Virus Illness

... who had gene mutation on both the copies. Among the Coloradans who were WNV-positive and who self-reported their race as white, the percentage of homozygous individuals was 8.3. In conclusion the researches said that CCR5 gene is very closely associated with the development of WNV infection. It would ...

Too much coffee is too bad

... and osteoporosis.They found that women with high caffeine intakes had significantly higher rates of bone loss at the spine, and that women who were homozygous for a mutation in the vitamin D receptor (VDR) gene were at greater risk for caffeine-related bone loss.// Women in the high cafeeine category ...
Other Contents
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
Other TagsOther Tags